Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in moderate to severe SLE
NCT04082416Phase 3Completed
- Sponsor
- RemeGen
- Start
- Oct 2019
- Primary completion
- Apr 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing RC18 160mg with Placebo (2 arms). Primary endpoint: SLE Responder Index (SRI) Response Rate at 52 weeks. Started Oct 2019; status: completed.
02
Drugs
telitacicept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04082416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04082416.